Srikant Kondapaneni, MD
Internal Medicine · Englewood, NJNPI 1447273867
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,317 of the $11,845 with a category attached, or 87.1%. It is spread thinly across 60 manufacturers, the largest accounting for just 9.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,555, 2.4 times the $1,082 reported in 2019. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 620 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$1K
- Harmony Biosciences LLC$1K
- Hill-rom Company, Inc$875
- Jazz Pharmaceuticals Inc.$854
- GSK$749
- Boehringer Ingelheim$624
- plus $7K from 54 others
Across 8 payments — averaging $17,544 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$140K
What the payments were for
- Speaking & faculty fees$8757%
- Food & beverage$10,31787%
- Education$6536%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- The Monarch Airway Clearance System$875
- The Vest System Model 105 Home Care$875
- The Vest System 205 Acute Care$875
- Inspire$404
- CHARTIS CATHETER$322
- ZEPHYR DELIVERY CATHETER$322
- ZEPHYR ENDOBRONCHIAL VALVE$322
- PULMONX CHARTIS TABLET CONSOLE$322
- ALIYA SYSTEM$177
- Prolastin-C Liquid$165
- FlowTriever$147
- ClotTriever$147
- Adempas$124
- UPTRAVI$118
How this compares
$11,845 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 12 | $295,223 |
| WakixPitolisant Hcl | 12 | $253,046 |
| XywavSodium,calcium,mag,pot Oxybate | 12 | $162,802 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 161 | $126,496 |
| Breo ElliptaFluticasone/Vilanterol | 184 | $82,217 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $34,728 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $27,802 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $12,764 |
| Arnuity ElliptaFluticasone Furoate | 43 | $11,243 |
| Spiriva RespimatTiotropium Bromide | 11 | $11,097 |
| EliquisApixaban | 17 | $9,902 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $9,510 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $8,008 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $7,546 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 135 | $3,877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi | $1,150 | $295,22312 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $749 | $255,305451 claims |
| Harmony Biosciences LLCWakix | $1,030 | $253,04612 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $619 | $44,23893 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $624 | $23,86131 claims |
| PfizerEliquis | $114 | $9,90217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Englewood
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.